embed embed share link link comment comment
" type="application/x-shockwave-flash" allowfullscreen="true" width="425" height="344">
Embed This Video close
Share This Video close
bookmark bookmark bookmark bookmark bookmark bookmark bookmark bookmark bookmark bookmark bookmark bookmark
embed test
Rate This Video embed
1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)
Tags For This Video tags
rate rate tags tags related related lights lights

OncoMed Pharmaceuticals- Capital Formation


William D. Waddill, Senior Vice President and Chief Financial Officer of OncoMed Pharmaceuticals, highlights the importance of capital formation to encourage investment in the biotechnology industry and spur job growth across the country. On behalf of BIO, Mr. Waddill is providing testimony today at a Senate Committee on Banking, Housing, and Urban Affairs hearing on “Spurring Job Growth through Capital Formation While Protecting Investors, Part II.”

In this video interview, Mr. Waddill shares highlights of his testimony, explains why he feels it’s critical for the federal government to help emerging biotech companies, and emphasizes why it is important for industry leaders to proactively engage in policy matters.

The Senate Committee hearing will focus on several bills that aim to support emerging biotechnology companies, including:

The Reopening American Capital Markets to Emerging Growth Companies Act (S. 1933) to create an “on-ramp” to the public market for emerging growth companies to allow a transition period for certain accounting and disclosure requirements, including Sarbanes-Oxley Section 404(b).

The Small Company Capital Formation Act (S. 1544) to reform SEC Regulation A by expanding its eligibility requirements to include companies conducting direct public offerings of up to $50 million.

The Private Company Flexibility and Growth Act (S. 1824) to increase the limit that requires private companies to register with the SEC from 500 to 2000 shareholders.

The Access to Capital for Job Creators Act (S. 1831) to require the SEC to revise Rule 506 of Regulation D to permit general solicitation in direct public offerings, broadening the investor base.

About OncoMed
Founded in 2003, OncoMed was created to serve the needs of oncology and hematology physicians, patients, manufacturers as well as the managed care organizations utilizing bio-oncology. In its focus to bring together the four major groups involved in the treatment process, OncoMed has emerged as a unique trusted partner to these groups. OncoMed is headquarted in Manhasset, NY and is licensed to deliver specialized bio-oncology prescriptions in all 50 states. OncoMed provides a comprehensive inventory of all chemotherapy and bio-oncology pharmaceuticals, including limited distribution products.